Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 20/20 | 0.85 |
| ▸ | DRD2 | P14416 | 20/20 | 0.85 |
| ▸ | HTR2A | P28223 | 20/20 | 0.85 |
| ▸ | DRD3 | P35462 | 11/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15788650 | 1.00 | HTR1A (0.85) | HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL17579942 | 1.00 | HTR1A (0.85) | HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL17579944 | 1.00 | HTR1A (0.85) | HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL22302323 | 0.93 | HTR1A (0.73) | HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL22302300 | 0.92 | HTR1A (0.71) | HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL17598625 | 0.92 | HTR1A (1.00) | HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL19824708 | 0.92 | HTR1A (1.00) | HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL17598631 | 0.92 | HTR1A (1.00) | HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL17598649 | 0.89 | HTR1A (1.00) | HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL19824743 | 0.89 | HTR1A (1.00) | HTR1ADRD2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594294-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024072930-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-04-04 | — | — | WO | disclosed |